Anti-TNF therapy infliximab (Remicade, Centocor) is now approved for the treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy.
Anti-TNF therapy infliximab (Remicade, Centocor) is now approved for the treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy. The FDA nod marks the 13th indication approved for the drug. In EXPRESS, a phase III clinical trial, eight out of 10 patients receiving induction therapy achieved a 75% improvement in their psoriasis by week 10. Remicade is also approved to treat inflammatory diseases in gastroenterology, dermatology, and rheumatology.
Exploring Challenges, Opportunities for Community Pharmacists in Tobacco Cessation
April 24th 2024By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.